SCHEMBL2964067

SCHEMBL2964067

Nc1ncnc2c1c(-c1ccc3[nH]c(Cc4ccccc4)nc3c1)nn2[C@H]1CC[C@@H](N2CCC(O)C2)CC1

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 20/20 0.70
▸ EGFR P00533 3/20 0.70
▸ ERBB2 P04626 3/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2967206 1.00 IGF1R (0.70) IGF1REGFRERBB2
SCHEMBL2964064 1.00 IGF1R (0.70) IGF1REGFRERBB2
SCHEMBL2958098 0.92 IGF1R (0.69) IGF1REGFRERBB2
SCHEMBL2956051 0.89 IGF1R (0.73) IGF1REGFRERBB2
SCHEMBL2963721 0.88 IGF1R (0.70) IGF1REGFRERBB2
SCHEMBL2953928 0.88 IGF1R (0.70) IGF1REGFRERBB2
SCHEMBL2953930 0.88 IGF1R (0.70) IGF1REGFRERBB2
SCHEMBL2956074 0.88 IGF1R (0.66) IGF1REGFRERBB2
SCHEMBL2961063 0.88 IGF1R (0.66) IGF1REGFRERBB2
SCHEMBL2956080 0.88 IGF1R (0.66) IGF1REGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885EGFR 591/4885ERBB2 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback